Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron chelation therapy.

Chaim M Hershko1, Gabriela M Link, Abraham M Konijn

  • 1Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.

Current Hematology Reports
|February 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

Journal of neural transmission (Vienna, Austria : 1996)·2020
Same author

Iron as a therapeutic target for Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society·2018
Same author

Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?

Antioxidants & redox signaling·2017
Same author

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Haematologica·2015
Same author

Iron overload and apoptosis of HL-1 cardiomyocytes: effects of calcium channel blockade.

PloS one·2014
Same author

Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Antioxidants & redox signaling·2013

New oral iron chelators like deferiprone and ICL670 offer improved compliance for thalassemia patients. Combined chelation therapy shows promise for those unresponsive to single-agent treatments.

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Background:

  • Deferoxamine (DFO) infusions improve survival in thalassemia but have poor patient compliance.
  • Oral iron chelators are being developed to enhance compliance and treatment outcomes.
  • Transfusional iron overload necessitates effective chelation strategies.

Purpose of the Study:

  • To review the efficacy of new oral iron chelators compared to deferoxamine.
  • To evaluate the potential of combined chelation therapy for iron overload.
  • To identify improved treatment options for patients with unsatisfactory chelation results.

Main Methods:

  • Review of current literature on oral iron chelators deferiprone and ICL670.
  • Comparison of iron excretion and cellular penetration of different chelators.

Related Experiment Videos

  • Analysis of clinical studies on the efficacy and tolerability of ICL670.
  • Assessment of combined chelation strategies involving different chelator types.

    • Main Results:

    • Deferiprone offers better cell penetration and potential cardioprotection than DFO, though with less total iron excretion.
    • ICL670 at 20 mg/kg daily may be as effective as parenteral DFO at 40 mg/kg daily.
    • Combined chelation therapy demonstrates additive efficacy, potentially improving outcomes in non-responders to monotherapy.

    Conclusions:

    • Oral iron chelators represent a significant advancement over parenteral DFO for thalassemia patients.
    • Combined chelation strategies may overcome limitations of monotherapy and improve iron overload management.
    • Further research into combined chelation is warranted to optimize treatment for complex cases.